Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05293041
Other study ID # ARG-01
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date March 27, 2022
Est. completion date March 2025

Study information

Verified date July 2023
Source Sahlgrenska University Hospital, Sweden
Contact Ellinor Wisen, MD
Phone +46313428171
Email ellinor.wisen@vgregion.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Infusion of Argipressin during hepatic resection surgery may reduce blood loss. It may also reduce transfusion requirements, and mitigate the perioperative inflammatory response compared to placebo. Subjects will be randomized to infusion of Argipressin or placebo during surgery. Blood loss, transfusion requirements, surgical data including length of stay in hsopital, inflammatory markers and markers of renal- intestinal- and cardiac injury will be assessed.


Description:

Hepatic resection is a major surgical intervention with high risk of substantial blood loss. The surgical means to reduce blood loss may impair perfusion and induce intestinal congestion. If blood flow to the liver can be influenced by pharmacological means, blood loss and transfusion requirements may be reduced. Moreover, the inflammatory system is involved in cancer development, and the anti-inflammatory properties of Argipressin may decrease the inflammatory response after hepatic surgery. Argipressin is an endogenous substance, and part of the body's response to stress and trauma. Argipressin affects V1-receptors to produce vasoconstriction. It is also involved in inflammatory reactions and affects platelets. Patients will be stratified according to planned type of surgery (open/laparoscopic) and planned extent of resection, and randomized to etiher infusion of Argipressin or placebo (normal saline) during surgery. In all other aspects, the participants will be treated according to the institution protocol for hepatic resection. The study drug will be started as soon as the central line is placed, and discontinued at the end of surgery. Hemodynamic data will be collected during surgery, and blood and urine-samples will be obtained during and after surgery for analysis of inflammatory markers and markers of organ injury.


Recruitment information / eligibility

Status Recruiting
Enrollment 248
Est. completion date March 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Participant planned for hepatic resection (open or laparoscopic, regardless of indication for surgery). 2. Age =18 years. 3. ASA class I-III. 4. Signed informed consent form Exclusion Criteria: 1. Participant does not understand the given information, and/ or cannot give written informed consent. 2. Simultaneous operation of tumor with other localization, or surgery for superficial single hepatic tumor less than 2 cm, expected to be of short duration and with minimal blood loss. 3. Terminal kidney failure (estimated preoperative GFR< 15 ml/min) 4. Pregnancy or lactation. 5. Known allergy to Empressin®. 6. Patient included in other interventional study, interacting with the endpoints in the present study, or previous randomization in this study. 7. Hyponatremia (S-Na < 130 mmol/L) 8. Patient considered ineligible for other surgical or medical reason. 9. Present infection. Patients with systemic inflammatory disease, inflammatory bowel disease or preoperative corticosteroid treatment will not be eligible for the subgroups where cytokines and interleukins are investigated.

Study Design


Intervention

Drug:
Argipressin
Infusion of Argipressin 0.8 U/ml, 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the treatment arm.
Placebo
Infusion of Normal Saline 0.056 ml/kg/h will be started as soon as the central line is placed, and continued until the end of surgery in the placebo arm.

Locations

Country Name City State
Sweden Sahlgrenska University Hospital Gothenburg

Sponsors (1)

Lead Sponsor Collaborator
Kristina Svennerholm

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blood loss Blood loss at the end of surgery, measured according to the investigator's instructions, by visual assessment of suction devises and gauze, and subtraction of ascites and irrigation fluids. through surgery, an average of 8 hours
Secondary Blood transfusion Blood transfusion (ml) at the end of surgery and at postoperative day 1 and 2 and 5 respectively. At end of surgery and until postoperative day 2 or 5 respectively
Secondary Inflammatory markers-regular Levels of White Blood Cell count, C Reactive Protein, Platelet count and Albumin at the end of surgery and postoperative day 1-5 Measured throughout the study until postoperative day 2 (laparoscopic resection) or postoperative day 5 (open resection)
Secondary Inflammatory markers- extended Levels of Interleukin (IL)-1 Beta, IL-6, IL-8, IL-10, Monocyte chemoattractant protein-1, Stromal Cell-Derived Factor-1 alpha, Intercellular Adhesion Molecule, Complement (C) 3a, C5b-9 at the end of surgery and postoperative day 1 and 2. Measured at throughout the study until postoperative day 2.
Secondary surgical data duration of Pringles manouvre (min), duration of resection phase (min) and surgery (min) at the end of surgery, approximately 5 hours after start of surgery
Secondary Tranexamic Acid use of tranexamic acid (mg) at the end of surgery, approximately 5 hours after start of surgery
Secondary CVP (anesthesiological data) achievement of CVP (central venous pressure) goal (mmHg), as recorded on the Phillips monitor. during surgery
Secondary Noradrenaline use (anesthesiologigal data) Total use of noradrenaline (micrograms/minutes of surgery/ bodyweight) during surgery
Secondary use of diuretics Furosemide use (mg) until postoperative day 1
Secondary urine output urine output (ml) until postoperative day 1
Secondary postoperative complications Postoperative complications including death and radicality of resection at 30-day follow up. 30 days after surgery
Secondary Length of stay Length of stay in hospital From admission in hospital to discharge, expected time 2-5 days but will be followed until actual discharge, which may be several months.
Secondary Plasma Creatinine (change in organ damage markers) Change in plasma creatinine (micro-mole/L) from baseline (before surgery) to postoperative day 2 and 5 respectively.
Secondary Urine samples (change in organ damage markers) Change in urine creatinine and urine [TIMP-2] x [IGFBP-7] (quota, no unit) from baseline to end of surgery, approximately 5 hours
Secondary Cardiac marker (change in organ damage markers) Change in hs- TNI (ng/L) from baseline to postoperative day 1
Secondary Lactate (change in organ damage markers) change in plasma lactate from baseline to postoperative day 1
Secondary I-FABP (change in organ damage markers) Change in I-FABP (ng/L) from baseline to postoperative day 1
See also
  Status Clinical Trial Phase
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Not yet recruiting NCT06434701 - Severe COVID-19 Infection in Children Presenting to EDs in Israel and England N/A
Enrolling by invitation NCT05020210 - Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
Completed NCT04084301 - Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury N/A
Completed NCT04597983 - Effect of 8-week Intake of 2S-hesperidin on Performance, Body Composition and Biochemicals Markers in Amateur Cyclists N/A
Not yet recruiting NCT05990933 - Role of Adrenaline in in the Inflammatory Response in Diabetes N/A
Not yet recruiting NCT06016023 - Evaluation of Macrophage Inflammatory Protein-1α as a Periodontal Disease Biomarker
Not yet recruiting NCT04608643 - Inflammatory Markers and Cbc Indices in Severely Malnourished Children
Recruiting NCT01934049 - Postoperative Recovery in Elderly Patients Undergoing Hip Hemi-arthroplasty Phase 4
Recruiting NCT01417923 - The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Phase 4
Terminated NCT01377441 - Effect of Intravenous Ibuprofen on Inflammatory Responses in Patients Undergoing Surgery With General Anesthesia. Phase 4
Completed NCT01301079 - Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia Phase 3
Terminated NCT00578578 - Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Phase 4
Recruiting NCT04611334 - The Effects of HRV Biofeedback on Chronic Kidney Disease Patient. N/A
Recruiting NCT03510702 - SCREENING OF EPIGENETIC BIOMARKERS (miRNAs) IN THE GINGIVAL SULCUS
Completed NCT03445234 - Blueberries, Bananas, Exercise Recovery N/A
Not yet recruiting NCT06450704 - Cerebral and Anti-inflammatory Response Through Exercise - Mechanisms In Depressive Disorders N/A
Not yet recruiting NCT05754294 - Electric Polarization of Red Blood Cells : A Cohort Study to Assess the Erythrocytes Membrane Integrity Through Charge Conservation, Following Cardiac Surgery.
Not yet recruiting NCT04386525 - Omega 3 and Ischemic Stroke; Fish Oil as an Option Phase 4
Completed NCT04864600 - CANDLE - A Study of Acute Health Effects of Exposure to Particles Generated by Candles N/A